Spots Global Cancer Trial Database for richter syndrome

Every month we try and update this database with for richter syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Allogeneic Stem Cell Transplant for CLL	NCT01629511	Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom...	Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus	18 Years - 70 Years	M.D. Anderson Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NCT06247540	Recurrent Trans... Refractory Tran... Richter Syndrom... Transformed Chr... Transformed Sma...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Nivolumab Positron Emissi... Rituximab Venetoclax	18 Years -	Northwestern University
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	NCT03010358	Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom...	Entospletinib Laboratory Biom... Obinutuzumab Pharmacological...	18 Years -	OHSU Knight Cancer Institute
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma	NCT03321643	Recurrent Diffu... Recurrent Trans... Refractory Diff... Refractory Tran... Richter Syndrom... Transformed Fol...	Atezolizumab Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Gemcitabine Magnetic Resona... Oxaliplatin Positron Emissi... Rituximab	18 Years -	National Cancer Institute (NCI)
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma	NCT03884998	Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Indolent Non-Ho... Lymphoplasmacyt... Marginal Zone L... Richter Syndrom...	Copanlisib Nivolumab	18 Years -	City of Hope Medical Center
Allogeneic Stem Cell Transplant for CLL	NCT01629511	Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom...	Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus	18 Years - 70 Years	M.D. Anderson Cancer Center
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)	NCT02576990	Mediastinal Lar... Richter Syndrom...	Pembrolizumab	18 Years -	Merck Sharp & Dohme LLC
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT05388006	Chronic Lymphoc... Richter Syndrom... Small Lymphocyt...	Acalabrutinib Durvalumab Venetoclax	18 Years -	Mayo Clinic
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma	NCT03884998	Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Indolent Non-Ho... Lymphoplasmacyt... Marginal Zone L... Richter Syndrom...	Copanlisib Nivolumab	18 Years -	City of Hope Medical Center
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NCT06247540	Recurrent Trans... Refractory Tran... Richter Syndrom... Transformed Chr... Transformed Sma...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Nivolumab Positron Emissi... Rituximab Venetoclax	18 Years -	Northwestern University
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome	NCT02846623	Chronic Lymphoc... Recurrent Trans... Refractory Tran... Richter Syndrom... Small Lymphocyt...	Atezolizumab Laboratory Biom... Obinutuzumab Venetoclax	18 Years -	M.D. Anderson Cancer Center
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	NCT04491370	B-cell Lymphoma Burkitt Lymphom... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Transformed Non... Richter Syndrom... Hodgkin Lymphom...	Polatuzumab ved...	12 Years - 70 Years	New York Medical College
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NCT06247540	Recurrent Trans... Refractory Tran... Richter Syndrom... Transformed Chr... Transformed Sma...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Nivolumab Positron Emissi... Rituximab Venetoclax	18 Years -	Northwestern University
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation	NCT02420912	Loss of Chromos... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Nivolumab	18 Years -	M.D. Anderson Cancer Center
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	NCT02285244	Prolymphocytic ... Recurrent Mantl... Recurrent Small... Refractory Chro... Richter Syndrom...	sotrastaurin ac... pharmacological... laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia	NCT02530515	Anemia Cancer Fatigue Chronic Lymphoc... Fever Infectious Diso... Lymphadenopathy Lymphocytosis Night Sweats Prolymphocytic ... Recurrent Chron... Richter Syndrom... Secondary Malig... Thrombocytopeni... Weight Loss	Ex Vivo-activat... Laboratory Biom...	-	M.D. Anderson Cancer Center
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	NCT04491370	B-cell Lymphoma Burkitt Lymphom... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Transformed Non... Richter Syndrom... Hodgkin Lymphom...	Polatuzumab ved...	12 Years - 70 Years	New York Medical College
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	NCT02285244	Prolymphocytic ... Recurrent Mantl... Recurrent Small... Refractory Chro... Richter Syndrom...	sotrastaurin ac... pharmacological... laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation	NCT05672173	Recurrent Trans... Refractory Tran... Richter Syndrom...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Fludarabine Ibrutinib Lisocabtagene M... Nivolumab Pheresis Positron Emissi...	18 Years -	City of Hope Medical Center
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome	NCT04978779	Relapsed Non Ho... Chronic Lymphoc... Refractory Chro... Richter Syndrom... MYC Amplificati... MYC Overexpress... MYC Translocati...	VIP152 BTKi	18 Years -	Vincerx Pharma, Inc.
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT05388006	Chronic Lymphoc... Richter Syndrom... Small Lymphocyt...	Acalabrutinib Durvalumab Venetoclax	18 Years -	Mayo Clinic
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma	NCT05025800	Aggressive B-Ce... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Composite Lymph... Indolent B-Cell... Refractory Aggr... Refractory Foll... Refractory Grad... Refractory High... Refractory Mant... Refractory Marg... Refractory Prim... Refractory Tran... Refractory Tran... Richter Syndrom...	CD47 Antagonist... Lenalidomide Rituximab	18 Years -	M.D. Anderson Cancer Center
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	NCT03010358	Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom...	Entospletinib Laboratory Biom... Obinutuzumab Pharmacological...	18 Years -	OHSU Knight Cancer Institute
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma	NCT03892044	Chronic Lymphoc... Recurrent Diffu... Refractory Diff... Richter Syndrom... Small Lymphocyt... Transformed Chr... Transformed Fol... Transformed Sma...	Duvelisib Nivolumab	18 Years -	Ohio State University Comprehensive Cancer Center
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation	NCT04679012	Richter Syndrom... Chronic Lymphoc...	Polatuzumab Ved... Rituximab Etoposide Prednisone Cyclophosphamid... Hydroxydaunomyc...	18 Years -	Weill Medical College of Cornell University
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma	NCT03892044	Chronic Lymphoc... Recurrent Diffu... Refractory Diff... Richter Syndrom... Small Lymphocyt... Transformed Chr... Transformed Fol... Transformed Sma...	Duvelisib Nivolumab	18 Years -	Ohio State University Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: